QT
CBIO

Quantbot Technologies’s Crescent Biopharma CBIO Stock Holding History

Quantbot Technologies’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20
Closed -$7K – 1422
2020
Q2 		$7K Buy
+20
New +$5.66K ﹤0.01% 962
2018
Q2 		– Sell
-12
Closed -$19K – 1312
2018
Q1 		$19K Sell
12
-66
-85% -$137K ﹤0.01% 1070
2017
Q4 		$131K Buy
+78
New +$103K 0.01% 796

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantbot Technologies's CBIO Position: Q3 2020 in Review

Quantbot Technologies sold out of Crescent Biopharma (CBIO) in Q3 2020, closing a stake of 20 shares — an estimated $7K sold.

Quantbot Technologies first reported a position in CBIO in Q4 2017 and held it in 3 quarters. The position peaked at $131K in Q4 2017. 80 funds tracked by Wall St. Rank hold CBIO as of Q3 2020.

  • Quantbot Technologies reported no remaining Crescent Biopharma position as of Q3 2020 after selling out during the quarter.
  • Quantbot Technologies sold 20 Crescent Biopharma shares in Q3 2020, an estimated $7K.
  • Quantbot Technologies first reported a position in Crescent Biopharma in Q4 2017 and held it in 3 quarters.
  • Quantbot Technologies's Crescent Biopharma position peaked at $131K in Q4 2017.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2020.

Based on Quantbot Technologies's 13F filing for Q3 2020, filed 16 Nov 2020.